A Single Arm, Open-label, Multicenter, Multinational, Safety and Efficacy Phase IIIb Trial of BI 695502 Plus mFOLFOX6 in Patients With Previously Untreated Metastatic Colorectal Cancer
Latest Information Update: 22 Nov 2019
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions; Registrational
- Acronyms INVICTAN-3
- Sponsors Boehringer Ingelheim
- 11 Oct 2018 Status changed from active, no longer recruiting to completed.
- 04 Jul 2018 Planned End Date changed from 30 Sep 2018 to 3 Oct 2018.
- 04 Jul 2018 Planned primary completion date changed from 30 Sep 2018 to 3 Oct 2018.